Skip to main content
SpringerLink
Log in

Current Trends of Treatment

  • Conference paper
The Medical Management of Prostate Cancer II

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Cancer of the prostate represents 10% of all cancers in males and recently became the second most frequent cancer in men in the industrial nations of West Europe and North America. This increase in incidence and mortality is small but real. The greying of the male population and the increasing detection of localised cancer by new technology probably account for most of this increase. The most recent survey of prostate cancer, organised by the American College of Surgeons, showed that close to 50% of the newly diagnosed cases presented with localised disease [1]. This exceptional change in trend to earlier diagnosis is due to increased awareness on the part of urologists and patients alike in the search for locally confined cancer. Also high-risk patients selected by transrectal ultrasound and/or elevated prostate cancer markers are more frequently diagnosed by ultrasound-guided biopsy. This fortuitous Situation is somewhat offset by the lack of consensus on preferred treatment, as revealed in a symposium organised by the National Institutes of Health of the USA [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Schmidt JD, Mettlin C: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982 (127):928–934

    PubMed  CAS  Google Scholar 

  2. Office of Medical Applications of Research, National Institutes of Health, Bethesda: The management of clinically, localised prostate cancer. J Am Med Ass 1987(258):2727–2730

    Article  Google Scholar 

  3. Denis L: The Medical Management of Prostatic Cancer-Monograph. European School of Oncology. Heidelberg, Springer-Verlag 1988

    Google Scholar 

  4. Cantrell BB, Deklerk DP, Eggleston JC, Boitnott JK, Walsh PC: Pathological factors that influence prognosis in stage A prostatic cancer: The influence of extent versus grade. J Urol 1981 (125):516–520

    PubMed  CAS  Google Scholar 

  5. Hermanek P, Sobin LH: TNM Classification of Malignant Tumours. International Union against Cancer, Geneva 1987, 4th edition

    Google Scholar 

  6. Gervasi LA, Mata J, Easly JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, Scardino PT: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989 (142):332–336

    PubMed  CAS  Google Scholar 

  7. Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, Sylvester R, Armitage TG, Members of the EORTC Urobgical Group: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: A sub-analysis of EORTC trial 30853. Cancer 1990 (66,5 Suppl):3–10

    Google Scholar 

  8. Mc Neal JE: The prostate gland: Morphology and pathobiology. In: Stamey TA (ed) Monographs in Urology: Prostate. Custom Publishing Services, Princeton 1988 pp 36–54

    Google Scholar 

  9. Jewett HJ, Bridge RW, Gray GF, Shelley WM: The palpable nodule of prostatic cancer. JAMA 1968 (203):403–406

    Article  PubMed  CAS  Google Scholar 

  10. Graversen PH, Gasser TC, Madsen PO, Corle DK: Early prostatic cancer: radical prostatectomy versus placebo. J Urol 1987 (131):364A

    Google Scholar 

  11. Van Aubel OGJM, Hoekstra WJ, Schroeder FH: Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 1985 (134):292–294

    PubMed  Google Scholar 

  12. Denis L: Current trends in prostatic cancer care. In: Furr BJA, Denis L (eds) Clinical Oncology: Prostate Cancer: International Practice and Research. Bailliäre Tindall, London 1988 2(3) pp 675–686

    Google Scholar 

  13. Newling D, Fossa S, Tunn U, Kurth KH, De Pauw M, Sylvester R, Members of the EORTC GU Group: Preliminary results of phase III study of mitomycin C versus estramustine in progressive metastatic prostate cancer refractory to hormonal therapy: Results of EORTC GU Group Study 30865. Eur Urol 1990 (18-suppl.1 ):2

    Google Scholar 

  14. Whitmore WW: Clinical management of prostatic cancer: An overview. Am J Clin Oncol (CCT) 1988 (11-Suppl 2):88–97

    Article  Google Scholar 

  15. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologic Pathology: The Prostate. Lea & Febiger, Philadelphia 1977 (part II) pp 171–198

    Google Scholar 

  16. Standaert B, Van Der Auwera JC, Chaban M, Cornet A, Eylenbosch W, Denis L: The use of transrectal echography for screening on prostate cancer: Results and evaluation. In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds) Prostate cancer Part B: Imaging techniques, radiotherapy, chemotherapy, and management issues. AR Liss, New York 1987 pp 29–36

    Google Scholar 

  17. Braeckman J, Denis L: The practice and pitfalls of ultrasonography in the lower urinary tract. Eur Urol 1983(9):193–201

    PubMed  CAS  Google Scholar 

  18. Lee F, Torp-Pedersen ST, Siders DB, Kumasaka GH, McHugh TA: The use of transrectal ultrasound in the study of normal and abnormal anatomy of the prostate gland. In: Labrie F, Lee F, Dupont A (eds) Diagnosis and Choice of Therapy: Early Stage Prostate Cancer. Elsevier Sci Publ, Amsterdam 1989 pp 23–36

    Google Scholar 

  19. Cooper EH, Armitage TH, Robinson MRG, Newling DWW, Richards BR, Smith PH, Denis L, Sylvester R: Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1989 (66,5-Suppl):19–22

    Google Scholar 

  20. Schröder FH, Cooper EH, Debruyne FMJ et al: TNM classification of genitourinary tumours 1987. Position of EORTC Genitourinary Group. Br J Urol 1988(62):502–510

    Article  PubMed  Google Scholar 

  21. Jones WG: Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC Genito-Urinary Group Report. World J Urol 1986 (4):176–181

    Article  Google Scholar 

  22. Denis L, Mettlin C: Conclusions. Proceedings workshop on combined castration and androgen blockade therapy in prostate cancer: Results and future directions. Cancer 1990 (66,5-suppl):80–83

    Google Scholar 

  23. Mettlin C, Denis L: Introduction. Proceedings workshop on combined castration and androgen blockade therapy in prostate cancer: Results and future directions. Cancer 1990 (66,5-suppl):2

    Google Scholar 

  24. Kirk D: Trial and tribulations in prostate cancer. Br J Urol 1987 (59):375–379

    Article  PubMed  CAS  Google Scholar 

  25. Altwein J: Estrogen in the treatment of prostate cancer. In: Pavone Macaluso M, Smith PH (eds) Cancer of the Prostate and Kidney. Plenum Press, New York 1983 pp 317–328

    Google Scholar 

  26. Denis L: Current trends in prostatic care. In: Furr BJA, Denis L (eds) Clinical Oncology: Prostate Cancer: International Practice and Research. Balliäre Tindall, London 1988 (2,3) pp 675–686

    Google Scholar 

  27. Aro J, Haapiainen R, Sane T, Rannikko S, Pelkonen R, Alfthan O: Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. Eur Urol 1989 (636):1–11

    Google Scholar 

  28. Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, De Pauw M, Sylvester R: A comparison of the effect of diethylstilbestrol and bw dose estramustine phosphate in the treatment of advanced prostatic cancer: A phase II trial of the EORTC Urological Group. J Urol 1986 (136):619–623

    PubMed  CAS  Google Scholar 

  29. Furr BJA, Milsted RAV: LH RH analogues in cancer treatment. In: Stoll BA (ed) Endocrine Management of Cancer 2: Contemporary Therapy. Karger, Basel 1988 pp 16–29

    Google Scholar 

  30. Denis L: Analogues de la LHRH. In: Khoury S, Chatelain C (eds) Urologie: Cancer de la Prostate. FUS, Paris 1988 pp 351–359

    Google Scholar 

  31. Newling DWW: The value of reversible androgen suppression as a diagnostic test. In: Murphy GP, Khoury S, Küss R, Chatelain C, Denis L (eds) Prostate Cancer Part A: Research, Endocrine Treatment and Histopathology. AR Liss, New York 1987 pp 261–265

    Google Scholar 

  32. Namer M: Rationale for medical castration. In: Furr BJA, Denis L (eds) Clinical Oncology: Prostate Cancer: International Practice and Research. Bailliäre Tindall, London 1988 pp 535–546

    Google Scholar 

  33. Blackard CE: The Veterans Administration Cooperative Uro logical Research Group studies of carcinoma of the prostate: A review. Cancer Chemother Reports1975 (59):225–227

    CAS  Google Scholar 

  34. Haapiainen R, Rannikko S, Alfthan O: Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer: A 2 year follow-up report of a national, prospective prostatic cancer study. Brit J Urol 1986 (58):528–533

    Article  PubMed  CAS  Google Scholar 

  35. Jacobi H, Neumann F: The Case for Cyproterone Acetate. Clinical Oncology: Prostate Cancer: International Practice and Research. Bailliäre Tindall, London 1988 2(3) pp 571–580

    Google Scholar 

  36. Crawford DE, Eisenberger MA, Mcleod D, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 (321):419–424

    Article  PubMed  CAS  Google Scholar 

  37. Denis L, Murphy G, Dalesio O: Workshop on a meta-analysis of trials involving combination treatment in prostatic cancer. Paris 1990

    Google Scholar 

  38. Suciu S, Sylvester RJ, Yamanaka H: Time-dependent prognostic factors in advanced prostatic cancer. In: Newling DWW, Jones WG (eds) Prostate Cancer and Testicular Cancer. Wiley-Liss, New York 1990 pp 203–215

    Google Scholar 

  39. Keuppens F, Fossa S, Nowé P, Denis L: Secondary orchiectomy in patients with prostatic cancer in relapse. In: Denis L, Murphy GP, Prout GR, Schröder FH (eds) Controlled Clinical Trials in Urologic Oncology. Raven Press, New York 1984 pp 207–209

    Google Scholar 

  40. Dente L, Murphy G, Droz P: Personal communication

    Google Scholar 

  41. Fossa SD, Ogreid P, Karlsen S, Havelan H, Jensen J, Trovag A: High dose medroxyprogesterone acetate (MPA) versus prednisolone (P) in hormone-resistant prostate cancer. In: Bracci U, Di Silverio F (eds) Advances in Urological Oncology and Endocrinology. Acta Medica, Rome 1984 pp 433–437

    Google Scholar 

  42. Denis L, Mahler C: LHRH agonist combination treatment. In: Motta M, Serio M (eds) Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects. Medicom, Amsterdam 1987 pp 85–92

    Google Scholar 

  43. Mahler C: Ketoconazole. In: Khoury S, Chatelain C (eds) Urologie: Cancer de la Prostate. FUS, Paris 1988 pp 365–368

    Google Scholar 

  44. Denis L, Mahler C, Ongena P, Janssen P, De Coster R, Bruynseels J: A phase l/ll study with R75251, a novel imidazole derivative in M1 prostate cancer patients in relapse. Abstract IXth Congress of the European Association of Urology, Amsterdam, 1990

    Google Scholar 

  45. Van Oosterom AT, De Smedt EA, Denis LJ, de Bruijn EA, Mahler C: Suramine for prostatic cancer: A phase l/ll study in advanced extensively pretreated disease. EJC 1990 (26,4):422

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Algemeen Ziekenhuis Middelheim, Lindendreef 1, 2020, Antwerp, Belgium

    Louis Denis

Authors
  1. Louis Denis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Algemeen Ziekenhuis Middelheim, Lindendreef 1, 2020, Antwerp, Belgium

    Louis Denis

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Denis, L. (1991). Current Trends of Treatment. In: Denis, L. (eds) The Medical Management of Prostate Cancer II. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76278-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76278-9_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76280-2

  • Online ISBN: 978-3-642-76278-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation